NeuralCipher Research overview
The text below is the source article’s original abstract under a verified reuse license. cc by
Parkinson's disease (PD), a neurodegenerative disorder marked by the progressive loss of dopaminergic neurons in the substantia nigra, imposes substantial economic burdens, including both direct and indirect costs. The medical community currently lacks a definitive cure for Parkinson's disease, and early detection is crucial for timely intervention and disease management. As innovative diagnostic tools, biosensors have shown great potential in detecting PD at its early stages. This review comprehensively summarizes recent advances in biosensors for the early detection of PD, with a particular focus on the detection of two key biomarkers: dopamine (DA) and α-synuclein (α-syn). Furthermore, it illustrates a variety of nanotechnology-based biosensors, including optical, electrochemical, and transistor biosensors, detailing their underlying principles, advantages, limitations, and applications in PD detection. Moreover, the review explores the challenges and prospects of advancing biosensors for early PD diagnosis.
Scientific assessment
Research question
Assess the question within the original study’s scope.
Methods & sample
Check the source article for study design and sample details.
Key findings
An editorially approved findings summary is not yet published for this record.
Limitations
Generalizability, bias and clinical meaning require separate assessment.
Methods, samples and clinical conclusions are not inferred from bibliographic metadata.